Journey Medical reports Q2 2026 results as Emrosi prescriptions climb

Journey Medical Corporation reported second quarter 2026 financial results and corporate highlights on August 12, 2026. The company is a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions.¹

On the commercial front, Emrosi total prescriptions were approximately 36,000 for the second quarter of 2026, compared to approximately 30,000 for the first quarter of 2026 and 27,000 for the fourth quarter of 2025.¹ CEO Claude Maraoui said momentum behind Emrosi remains strong, with sales of the product up significantly compared to both the prior-year period and the first quarter of this year.¹ He added that prescription demand and payer coverage for Emrosi are increasing as the company establishes the product as the best-in-class oral treatment for patients suffering from rosacea.¹

Financially, total revenues were $18.5 million for the second quarter of 2026, a 23% increase from $15.0 million for the second quarter of 2025, driven by continued commercial demand momentum for Emrosi, which generated revenues of $8.1 million for the quarter.¹ GAAP net loss narrowed to $0.3 million, or $(0.01) per share basic and diluted, for the second quarter of 2026, compared to a net loss of $3.8 million, or $(0.16) per share basic and diluted, for the second quarter of 2025.¹

On cash, at June 30, 2026, the company had $25.6 million in cash and cash equivalents, as compared to $24.1 million in cash and cash equivalents at December 31, 2025.¹ Maraoui said with this progress and over $25 million in cash, the company believes it is well-positioned to execute on its strategy and deliver strong financial performance going forward.¹

The release did not disclose new clinical trial starts, regulatory filings, or changed timelines for Emrosi or other pipeline candidates.